Key Points
- Insider buying: 4basebio insider Amy Walker bought 1,863 shares on May 20 at an average price of GBX 509, for a total of about £9,483.
- Stock move: 4basebio shares were up 7.2% and opened at GBX 520, trading within a 52-week range of GBX 420 to GBX 1,150.
- Recent results: The company reported quarterly EPS of GBX (1.09) on revenue of GBX 169 million, while analysts expect full-year EPS of -3.43.
4basebio PLC (LON:4BB - Get Free Report) insider Amy Walker acquired 1,863 shares of the business's stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average price of GBX 509 per share, with a total value of £9,482.67.
4basebio Trading Up 7.2%
Shares of 4basebio stock opened at GBX 520 on Friday. 4basebio PLC has a fifty-two week low of GBX 420 and a fifty-two week high of GBX 1,150. The firm has a market cap of £80.52 million, a price-to-earnings ratio of -5.25 and a beta of 1.09. The company has a quick ratio of 3.52, a current ratio of 2.73 and a debt-to-equity ratio of 201.47. The business has a fifty day simple moving average of GBX 496.21 and a 200-day simple moving average of GBX 578.93.
4basebio (LON:4BB - Get Free Report) last announced its earnings results on Wednesday, May 20th. The company reported GBX (1.09) EPS for the quarter. The firm had revenue of GBX 169 million during the quarter. On average, equities analysts forecast that 4basebio PLC will post -3.43 EPS for the current fiscal year.
About 4basebio
(
Get Free Report)
4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.
Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
